IN8BIO, INC. Files 8-K Report
Ticker: INAB · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
IN8BIO, INC. filed an 8-K on 12/10/24, updating its address and former name.
AI Summary
On December 10, 2024, IN8BIO, INC. filed an 8-K report. The filing indicates the company's principal executive offices are located at 350 5th Avenue, Suite 5330, New York, NY 10118. The company was formerly known as Incysus Therapeutics, Inc. until May 10, 2018.
Why It Matters
This 8-K filing provides updated corporate information for IN8BIO, INC., including its current address and former company name, which is important for investors and stakeholders tracking the company's official disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant financial or operational news that would inherently increase risk.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- December 10, 2024 (date) — Date of earliest event reported
- 350 5th Avenue, Suite 5330 New York, New York 10118 (address) — Principal Executive Offices
- Incysus Therapeutics, Inc. (company) — Former Name
- May 10, 2018 (date) — Date of Name Change
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated December 10, 2024.
What is the principal executive office address for IN8BIO, INC.?
The principal executive offices are located at 350 5th Avenue, Suite 5330, New York, New York 10118.
What was IN8BIO, INC.'s former company name?
IN8BIO, INC. was formerly known as Incysus Therapeutics, Inc.
When did the company change its name from Incysus Therapeutics, Inc.?
The date of the name change was May 10, 2018.
What is the SEC file number for IN8BIO, INC.?
The SEC file number for IN8BIO, INC. is 001-39692.
Filing Stats: 464 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-12-10 07:15:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d888773d8k.htm (8-K) — 25KB
- d888773dex991.htm (EX-99.1) — 20KB
- g888773g1210065754194.jpg (GRAPHIC) — 2KB
- 0001193125-24-273953.txt ( ) — 178KB
- inab-20241210.xsd (EX-101.SCH) — 3KB
- inab-20241210_lab.xml (EX-101.LAB) — 18KB
- inab-20241210_pre.xml (EX-101.PRE) — 11KB
- d888773d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated December 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IN8bio, Inc. Dated: December 10, 2024 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)